Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer’s disease
Open Access
- 1 January 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (1), eabb0457
- https://doi.org/10.1126/sciadv.abb0457
Abstract
The pathological relevance of naturally occurring antibodies to β-amyloid (NAbs-Aβ) in Alzheimer’s disease (AD) remains unclear. We aimed to investigate their levels and associations with Aβ burden and cognitive decline in AD in a cross-sectional cohort from China and a longitudinal cohort from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. NAbs-Aβ levels in plasma and cerebrospinal fluid (CSF) were tested according to their epitopes. Levels of NAbs targeting the amino terminus of Aβ increased, and those targeting the mid-domain of Aβ decreased in both CSF and plasma in AD patients. Higher plasma levels of NAbs targeting the amino terminus of Aβ and lower plasma levels of NAbs targeting the mid-domain of Aβ were associated with higher brain amyloidosis at baseline and faster cognitive decline during follow-up. Our findings suggest a dynamic response of the adaptive immune system in the progression of AD and are relevant to current passive immunotherapeutic strategies.Funding Information
- National Natural Science Foundation of China (91749206)
- National Natural Science Foundation of China (81625007)
- National Natural Science Foundation of China (81671277)
- National Natural Science Foundation of China (81600936)
- Chinese Ministry of Science and Technology (2016YFC1306401)
This publication has 37 references indexed in Scilit:
- NEWS FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCENeurology Today, 2013
- Autoreactive‐Aβ antibodies promote APP β‐secretase processingJournal of Neurochemistry, 2011
- Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer diseaseNeurology, 2011
- The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's diseaseInternational Psychogeriatrics, 2009
- Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's diseaseProceedings of the National Academy of Sciences of the United States of America, 2009
- Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Aβ(25–35) oligomers, S100b and neurotransmittersJournal of Neuroimmunology, 2007
- Immunology and immunotherapy of Alzheimer's diseaseNature Reviews Immunology, 2006
- Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptideBiological Psychiatry, 2005
- Autoantibodies to Amyloid β-Peptide (Aβ) are Increased in Alzheimer's Disease Patients and Aβ Antibodies Can Enhance Aβ Neurotoxicity: Implications for Disease Pathogenesis and Vaccine DevelopmentNeuroMolecular Medicine, 2003
- A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMRProceedings of the National Academy of Sciences of the United States of America, 2002